A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects with Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy
Latest Information Update: 12 Jul 2024
Price :
$35 *
At a glance
- Drugs Efavaleukin alfa (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Amgen
- 29 Aug 2023 This trial has been completed in Austria, according to European Clinical Trials Database record.
- 27 Apr 2023 Status changed to discontinued for futility as per Amgen media release.
- 21 Apr 2023 Planned End Date changed from 26 Jan 2025 to 18 May 2023.